ABCELLERA BIOLOGICS (8QQ) — Tangible Net Worth Ratio
ABCELLERA BIOLOGICS (8QQ) has a Tangible Net Worth Ratio of 95.9% as of June 2026. This metric is calculated by deducting intangible assets (€36.53 Million) from net assets (€896.02 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore how fast is ABCELLERA BIOLOGICS growing its equity to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
ABCELLERA BIOLOGICS Tangible Net Worth Ratio (2021–2025)
This chart shows how ABCELLERA BIOLOGICS's Tangible Net Worth Ratio has changed across 5 annual periods from 2021 to 2025. As of June 2026, the ratio stands at 95.9%, reflecting net assets of €896.02 Million with intangible assets of €36.53 Million EUR. For live market cap and overall valuation, see ABCELLERA BIOLOGICS (8QQ) total market value.
Annual Tangible Net Worth Ratio for ABCELLERA BIOLOGICS (2021–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for ABCELLERA BIOLOGICS from 2021 to 2025, covering 5 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore ABCELLERA BIOLOGICS (8QQ) reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 96.0% | €966.90 Million | €38.38 Million | €1.36 Billion | ▲ +0.0 pp |
| 2024 | 96.0% | €1.06 Billion | €42.11 Million | €1.36 Billion | ▲ +6.5 pp |
| 2023 | 89.5% | €1.15 Billion | €120.42 Million | €1.49 Billion | ▲ +0.2 pp |
| 2022 | 89.3% | €1.23 Billion | €131.50 Million | €1.54 Billion | ▲ +3.8 pp |
| 2021 | 85.5% | €1.03 Billion | €148.39 Million | €1.32 Billion | — |